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Breast cancer surgery and angiogenesis:
Stem cell cycle may explain heterogeneity
of recurrenceDear Editor
In the article by Retsky et al.1 the first peak
of recurrence is explained by the breaking of
dormancy which occurs at surgery. Within this
peak these authors propose two surgery-acceler-
ated relapse modes, the first at 10 months due
to avascular micrometastases stimulated to de-
velop a vasculature and a second at 18e40
months resulting from single cells induced to
proliferate. These two modes may exist and, al-
though not addressed specifically in this publica-
tion, they may begin to explain differences in
response to therapy which occurs for the first
peak. However, they are insufficient to com-
pletely explain the differences in response. Dem-
icheli et al.2 compared women treated with
mastectomy alone to women treated with mas-
tectomy plus adjuvant CMF. The graphs of the
hazard rate for treatment failure versus time re-
vealed no effect on the timing of the first peak
but decrease its height, the area under the curve
and, therefore, the number of patients who re-
cur at this time point. Likewise, Howell et al.3
presented data from the ATAC trial at the 2004
San Antonio Breast Cancer Symposium which rev-
eled that anastrozole produces the same result:
patients treated with anastrozole had a decease
in the height of the first peak. In both cases,
however, there remain patients receiving therapy
who recurred in the first peak. Why the lack of
a uniform response? Inherent resistance is one
possibility. I would argue that another possibility
is that these dormant cells are breast cancer
stem/progenitor cells which are residing in
a stem cell niche in G0. Beginning as early1743-9191/$ - see front matter ª 2005 Published by Elsevier Ltd ostem-cells, stem-cells mature through a number
of stages eventually becoming committed pro-
genitor cells and then mature, differentiated
cells. Each of these types of stem-cells or progen-
itor cells theoretically can be the target of the
transforming event(s). Tumors derived from early
stem-cells, which by definition are mulitpotential,
are hypothesized to lead to a more heterogeneous
phenotype than those derived from later, differen-
tiated cells. Tu et al.4 have hypothesized that
tumors derived from early stem-cells have in-
creased metastatic potential. Because early stem-
cells maintain their multipotentiality, it is also
hypothesized that they have a more diversified
growth factor and chemokine receptor profile
which may be responsible for the increased meta-
static potential. The cells responding to the act
of operating may be early stem-cells propelled
out of G0 by a soluble, circulating substances re-
leased to promote wound healing. These early
stem-cells would be predicted to produce hetero-
geneous recurrences only some of which are sensi-
tive to chemo/endocrine/biologic therapy. This
possibility will be important as perioperative ther-
apies, e.g., antiangiogenic therapies suggested by
the authors, are contemplated.
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Dear Editor
Dr. Retsky’s1 explanation for the early peak in
recurrence rate in the early period after surgery
is quite plausible and most interesting. Another
possible explanation is the heterogeneity of the
disease. There is variability in the rate of
growth of breast cancers, with the more aggres-
sive tumors recurring early. These are then
removed from the at-risk population, leaving
tumors that grow more slowly. Assuming at least
a moderate proportion of aggressive tumors the
effect would be a clear early peak in the recur-
rence rate. The longer term recurrence rate
would be much lower than that in the early
period following surgery. The rub, of course, is
that today’s science does not enable very
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Dear Editor
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angiogenesis in early breast cancers. This is
another piece of evidence relevant to the question
of whether screening for cancers in women under
50 is beneficial (reduces mortality) or possibly
